ArticleFrontiers in pharmacology2025
Drug-induced dermatomyositis: a pharmacovigilance study of the FDA adverse event reporting system.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dermatomyositis Mimicking Statin-Induced Myopathy in A 62-Year-Old Woman.European journal of case reports in internal medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dermatomyositis (DM) is an autoimmune disease that may be triggered by certain medications. However, most studies have focused on specific drugs, lacking a comprehensive overview. This study uses the FDA's Adverse Event Reporting System (FAERS) to explore the correlation between DM and medications. Research design and methods: The study encompassed FAERS reports from January 2004 to June 2024. We coded and classified adverse events (AEs) using MedDRA and conducted multiple disproportionality analyses (ROR, PRR, BCPNN, MGPS) to examine drug-event associations and analyze the results. Results: Using the "primary suspects" role code in FAERS, 1767 reports involving 353 drugs suspected of inducing DM were identified. Among 24 signal-positive drugs, cardiovascular drugs (297 reports, mainly statins) were most frequent, followed by immunotherapy agents (188 reports, mainly Immune Checkpoint Inhibitors) and chemotherapy agents (147 reports, mainly Antimetabolites). Conclusion: This study on drug-induced DM presents a new approach to rational and evidence-based drug prescribing. It leverages advanced model algorithms to significantly improve the precision in predicting drug-DM correlations, enhancing patient safety. Additionally, the study provides clinicians with guidance on avoiding medications associated with DM in patients with predisposing factors that may increase their risk of developing the condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.